pharmaceuticals

Tirzepatide Could Replace Daily Hormone Shots for Rare Genetic Fat Disorder

by

Revolutionizing Treatment for Congenital Generalized Lipodystrophy (CGL) Recent advancements in medical research have uncovered promising new treatments for Congenital Generalized Lipodystrophy (CGL), a rare genetic disorder that leaves patients with almost no fat tissue. A new study highlights the potential of once-weekly tirzepatide injections to replace daily hormone shots, marking a significant leap in patient … Read more

Novo Nordisk’s Ozempic wins FDA approval for chronic kidney disease

by

Ozempic’s Breakthrough in Chronic Kidney Disease Treatment The Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic, a GLP-1 receptor agonist, for chronic kidney disease prevention in adults with Type 2 diabetes. This means Ozempic can now be used to prevent kidney disease from worsening, reducing kidney failure, and lowering the risk of cardiovascular … Read more

Current Kidney Transplant Policies Disadvantage Certain Adolescents, Young Adults

by

Unveiling Inequities in Kidney Transplant Allocation: A Call for Change Recent research highlights critical inequities in kidney transplant allocation policies, especially impacting patients who began dialysis as children but were waitlisted as adults. This disparity, often referred to as the “pediatric advantage,” calls for urgent policy revisions to ensure equitable access to high-quality grafts for … Read more

Testing Thousands of Compounds Simultaneously to Uncover New Drugs and Tailored Treatments

by

Revolutionizing Drug Discovery with AI and Metabolomics The landscape of drug development is undergoing a profound transformation, propelled by advancements in artificial intelligence (AI) and high-throughput metabolomics. Researchers at the University of Basel have pioneered a method that allows the simultaneous testing of over 1,500 active substances on cell metabolism. This groundbreaking approach not only … Read more

Trump health care plan likely good for pharmaceutical companies

by

Healthcare Under the Trump Administration: What to Expect Revamping Drug Pricing Strategies As the Trump administration takes office, pharmaceutical companies anticipate shifts in drug pricing policies. Unlike the hardline approach of the Biden administration, Trump may prioritize cost-cutting by targeting pharmacy benefit managers (PBMs) rather than directly implementing price controls on drugs. This change could … Read more

Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use

by

The Evolving Landscape of GLP-1 RA Therapy and Its Implications for Thyroid Cancer As the global prevalence of type 2 diabetes (T2D) and obesity continues to rise, so too does the use of GLP-1 receptor agonists (GLP-1 RAs) for managing these conditions. A recent study published in JAMA Otolaryngol Head Neck Surg sheds light on … Read more

Non-Urgent ED Utilization High For People With PsA, AS in Rural Areas

by

Understanding Emergency Department Use for Psoriatic Arthritis and Ankylosing Spondylitis Recent studies highlight a critical trend in healthcare where individuals with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) often turn to emergency departments (EDs) for non-urgent issues. This recurring pattern shines a light on the accessibility challenges faced, particularly in rural areas, and the pressing … Read more

Fall Prevention Strategies Needed for Adults With COPD

by

Fall Risks and COPD: Understanding the Connection New research indicates a significant association between high fall-risk increasing drug (FRID) burden and injurious falls among adults with chronic obstructive pulmonary disease (COPD) near the end of life.1 This study, led by Dr. Cara L. McDermott, reveals the complexities in managing COPD symptoms while minimizing the risk … Read more

GLP-1 RAs Provide Greater Hepatic Benefit Than SGLT2is For MASLD, Type 2 Diabetes

by

The Evolving Landscape of Liver Disease Treatment: GLP-1 Receptor Agonists vs. SGLT2 Inhibitors Recent studies have spotlighted the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over sodium-glucose cotransporter-2 inhibitors (SGLT2i) in managing liver conditions associated with type 2 diabetes (T2D). This breakthrough has potential ramifications for the future of liver disease treatment, particularly for … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: office@newsy-today.com

For contact, advertising, copyright, issues email: office@newsy-today.com